Research programme: antibody-based cancer immunotherapies - Agenus/Merck

Drug Profile

Research programme: antibody-based cancer immunotherapies - Agenus/Merck

Latest Information Update: 08 Jun 2015

Price : $50

At a glance

  • Originator Agenus; Merck AG
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 03 Jun 2015 Merck extends immuno-oncology collaboration with Agenus
  • 09 Apr 2015 Agenus acquires SECANT® yeast display platform from Celexion
  • 28 Apr 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top